An eight-week multicenter study to evaluate the efficacy and safety of the combination of aliskiren/ HCTZ [hydrochlorothiazide] (300/12.5 mg and 300/25 mg) in comparison with aliskiren 300 mg in patients with essential hypertension not adequately responsive to aliskiren 300 mg monotherapy

Trial Profile

An eight-week multicenter study to evaluate the efficacy and safety of the combination of aliskiren/ HCTZ [hydrochlorothiazide] (300/12.5 mg and 300/25 mg) in comparison with aliskiren 300 mg in patients with essential hypertension not adequately responsive to aliskiren 300 mg monotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Aliskiren; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 13 Aug 2007 Status changed from in progress to completed.
    • 07 Jun 2007 Status changed from recruiting to in progress.
    • 17 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top